Scientists hunt for genetic clues in advanced prostate cancer

NCT ID NCT01953640

Ongoing Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that may help predict how well patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify genetic markers that predict how well prostate cancer patients respond to CYP-17 inhibition therapy.
What could go wrong: This is an observational study focused on lab analysis, not a treatment trial. It may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma hormone-resistant prostate carcinoma metastatic prostate carcinoma prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE-RESISTANT PROSTATE CANCER METASTATIC PROSTATE CARCINOMA PROSTATE ADENOCARCINOMA RECURRENT PROSTATE CARCINOMA

Contacts and locations

Show contact details

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.